AtomVie Global Radiopharma (AtomVie), a leading radiopharmaceutical CDMO, announced that it has successfully supplied the first dose of Ariceum Therapeutics' (Ariceum) 225Ac-SSO110, a potentially first- and best-in-class Actinium-225-labelled antagonist of the somatostatin type 2 receptor (SSTR2), being evaluated in Ariceum's Phase 1/2 clinical trial (SANTANA-225) for the treatment of extensive-stage small cell lung cancer (SCLC) and Merkel Cell Carcinoma (MCC).

With this partnership, AtomVie is leveraging its state-of-the-art cGMP facilities and deep technical expertise to enable the robust and reliable manufacturing of 225Ac-SSO110. This collaboration secures a consistent supply and uncompromising quality of 225Ac-SSO110 to support the SANTANA-225 study.

"We are honored to partner with Ariceum to deliver the critical supply of 225Ac-SSO110 for the SANTANA-225 clinical trial. Our mission of transforming patients' lives with high quality radiopharmaceuticals drives every step of our work, and we are proud to contribute to bringing promising therapies in oncology closer to patients." said Bruno Paquin, CEO of AtomVie.

"Dosing the first patient in our SANTANA-225 clinical trial marks a significant milestone for Ariceum," said Manuel Sturzbecher-Höhne, Chief Technology Officer of Ariceum Therapeutics. "We are proud to partner with AtomVie on the manufacturing of 225Ac-SSO110. Their proven GMP expertise and unwavering commitment to quality give us confidence as we advance 225Ac-SSO110 through clinical development, and deliver on our mission to bring transformative therapies to patients facing these aggressive and underserved cancers."